Hanmi started to develop the first generic of Nexavar, a targeted anti-cancer drug

Hanmi Pharm has begun to develop the first generic of Nexavar(generic name: sorafenib), a liver cancer treatment.

According to the Ministry of Food and Drug Safety on the 16^th, it has recently approved a plan to conduct bioequivalent tests of sorafenib, applied by Hanmi Pharm.

Nexavar, a multi-target anti-cancer drug, has indication for kidney cancer and thyroid cancer as well as liver cancer...